The drug, which is used mainly to delay the progression of multiple sclerosis, has been on the
market since 2006. It originally went on the
market in 2005 but was removed due to medical problems that some patients encountered, Bloomgren said.
Tysabri is expensive, costing about $40,000 a year. It dampens the immune system, potentially reducing the inflammation that is a major part of multiple sclerosis.